Until recently, SCCHN treatment lacked promising late-phase agents; the only targeted therapy approved for the indication was Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. However, the…
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…
Angiogenesis inhibitors are the mainstay of the treatment of advanced renal cell carcinoma. However, the treatment algorithm is rapidly evolving driven by the approval of novel agents, including…
Consolidation within the oncology provider community, including hospital acquisitions of oncology practices and oncology practices joining together, is changing the dynamics in the relationship…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA…
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-…
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China and South Korea. The prevalence of this chronic disease remains high owing to the…
The treatment landscape for advanced/metastatic renal cell carcinoma includes well-established angiogenesis and mTOR inhibitors, many of which have broad labels allowing their use across several…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The 2013-2015 FDA…
The therapeutic landscape for recurrent or metastatic SCCHN has benefited from the introduction of only one novel treatment in the past several years, Erbitux in 2011. Although Erbitux has improved…
Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival…
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China. The prevalence of this chronic disease remains high owing to the presence of a large…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…